TNF-α Inhibitors Decrease Classical CD14^hiCD16- Monocyte Subsets in Highly Active, Conventional Treatment Refractory Rheumatoid Arthritis and Ankylosing Spondylitis.

ABSTRACT: Monocytes are pivotal cells in inflammatory joint diseases. We aimed to determine the effect of TNF-α inhibitors (TNFi) on peripheral blood monocyte subpopulations and their activation in ankylosing spondylitis (AS) and rheumatoid arthritis (RA) patients with high disease activity. To address this, we studied 50 (32 AS, 18 RA) patients with highly active disease with no prior history of TNFi use who were recruited and assigned to TNFi or placebo treatment for 12 weeks. Cytometric and clinical assessment was determined at baseline, four, and 12 weeks after initiation of TNFi treatment. We observed that treatment with TNFi led to a significant decrease in CD14^hiCD16- monocytes in comparison to placebo, while circulating CD14^dimCD16+ monocytes significantly increased. Th

SUBMITTER: Batko B 

PROVIDER: S-EPMC6358965 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature